Delfa bets voice AI agents fix trial enrollment; $3.8M seed, 50+ trials

Delfa runs AI voice agents that prescreen, answer questions, book visits and enroll patients for clinical trial sites by phone, SMS or chat in any language, writing results into a site's CRM or CTMS; by August 2025 it was live across 50+ trials, mostly with US sites.

Voice AI agents can replace the phone-tag funnel that eats a third of clinical-trial cost and delay; enrollment data then becomes the wedge to an AI-native trial OS.

$3.8M seed led by Air Street Capital with Saras Capital, announced 2025-08-25.

Tom Farrand (CEO) and Gustav Bredell (CTO) went through Entrepreneurs First as prospective founders in September 2024; Farrand kept returning to Bredell's observation that PhD-level colleagues spent their days cold-calling people to fill trials. After roughly 300 conversations with contract research organizations, they founded Delfa in 2025 on the thesis that voice AI had finally crossed the quality threshold needed to automate outreach.

Delfa's agents prescreen for medical eligibility, answer questions, collect histories and book visits in any language, with every interaction logged, scored against 20+ QA metrics and audited by physicians. By August 2025 it was live across 50+ trials with site networks Flourish, Elevate and Re:Cognition; Elevate reported hitting 125% of a migraine study's target while saving thousands of recruiter hours, and Delfa was in talks to pilot with two of the top 20 global pharma companies. In August 2025 it raised a $3.8M seed led by Air Street Capital to build an AI-native CRM and deeper clinical-operations integrations.

Enrollment is a third of trial cost and delay yet runs on spreadsheets and cold calls — a manual bottleneck too painful to ignore and too repetitive for humans to do well.

Voice AI crossed a quality threshold: agents handle eligibility nuance in any language while every interaction stays logged, scored and physician-audited for compliance.

Customers feel the win immediately — Elevate hit 125% of a migraine study's target and saved thousands of recruiter hours, beating a competing AI startup head-to-head.

The first-contact funnel produces the data for the next product, an AI-native CRM and trial-operations OS, making each conversation an asset rather than a cost.

Attack the most broken bottleneck in a regulated market: automate first contact with voice agents, prove ROI in hours saved, then turn every logged interaction into the system of record.

As of 2026-09-02 Delfa remains live and early-stage: the sources reviewed show no later public round or exit beyond the August 2025 seed, earmarked for the CRM, clinical-operations integrations and engineering hires. Its ambition is to move from recruitment to an AI-native operating system spanning site selection, study start-up and patient retention, selling directly to pharma. Watch items: proving voice agents hold up across indications and regulatory jurisdictions, and turning site-network wins into the system of record Salesforce, HubSpot, Medidata and Veeva don't cover.